Horizon Pharma Public Limited Company (HZNP)
(Delayed Data from NSDQ)
$26.54 USD
+0.55 (2.12%)
Updated May 3, 2019 04:00 PM ET
After-Market: $26.52 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$26.54 USD
+0.55 (2.12%)
Updated May 3, 2019 04:00 PM ET
After-Market: $26.52 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Is Horizon Pharma (HZNP) Poised for a Beat in Q1 Earnings?
by Zacks Equity Research
Horizon Pharma plc (HZNP) is scheduled to report first-quarter 2017 results before the opening bell on May 8.
What's in Store for Mallinckrodt (MNK) This Earnings Season?
by Zacks Equity Research
Mallinckrodt plc (MNK) is set to report first-quarter fiscal 2017 results on May 8.
Horizon (HZNP) Down 10.2% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Horizon (HZNP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Can Horizon Pharma (HZNP) Be a Great Stock for Value Investors?
by Zacks Equity Research
Horizon Pharma (HZNP) can Be a Great Stock for Value Investors on the back of its strong key value statistics.
Horizon (HZNP) Misses on Earnings in Q4, View Disappoints
by Zacks Equity Research
Horizon Pharma's (HZNP) fourth quarter results were disappointing with the company missing on both top- and bottom line estimates. Moreover, the guidance for 2017 also fell short of expectations.
Horizon Pharma (HZNP) Misses Q4 Earnings & Revenues
by Ekta Bagri
Horizon Pharma???s fourth-quarter 2016 earnings missed expectations.
Horizon (HZNP) Q4 Earnings: Stock Likely to Disappoint?
by Zacks Equity Research
Horizon Pharma plc (HZNP) is scheduled to report fourth-quarter 2016 results on Feb 27, before the opening bell.
Horizon's Rare Disease Drug Quinsair Launched in Canada
by Zacks Equity Research
Horizon Pharma plc (HZNP) announced the availability of Quinsair (levofloxacin inhalation solution) in Canada for the management of chronic pulmonary infections.
Horizon (HZNP) Stock Sinks, Friedreich's Ataxia Study Fails
by Zacks Equity Research
Horizon Pharma (HZNP) has decided to discontinue the development of Actimmune for Friedreich's ataxia after a phase III study failed to meet key endpoints.
Top Research Reports for 29th November, 2016
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth (UNH), 21st Century Fox (FOXA) and Sanofi (SNY).
This Week's Top Value Stocks: (HZNP) (DF)
by Tracey Ryniec
Value stock strategist, Tracey Ryniec, profiles Horizon Pharma Plc (HZNP) and Dean Foods (DF).
PEG Ratio vs. the P/E Ratio
by Kevin Matras
Kevin Matras compares the PEG ratio to the P/E ratio and shows how to use them both for finding classically undervalued stocks with market beating growth rates. Highlighted stocks include SIMO, ORBK, NTI, HZNP and AIRM.
A Company's First Profit Can Mean Big Profits to Investors
by Kevin Matras
Kevin Matras screens for companies showing their 'first' profit, and explains why they are ones to watch. Highlighted stocks include POZN, XCRA, NM, KEM and HZNP.